Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT

Bone Marrow Transplantation

Volumn 42, Issue SUPPL. 2, 2008, Pages

  Glowka F K ^a   Karazniewicz Lada M ^a   Grund, G ^a   Wrobel T ^a   Wachowiak, J ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

TREOSULFAN;

ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADRENOLEUKODYSTROPHY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REFRACTOMETRY; REVIEW; WISKOTT ALDRICH SYNDROME;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 55749110938     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.287     Document Type: Review

References (11)

1. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1999; 79: 264-266.
2. Boobis A, Rawlins M, Thomas S, Wilkins M. Treosulfan. In: Dollery C (ed). The Drugs. Churchill Livingstone: Edinburgh, 1999, pp 161-163.
3. Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998; 42: 99-104.
4. Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S et al Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol 2000; 45: 483-488.
5. Hilger RA, Baumgart J, Scheulen ME, Trenschel R, Strumberg D, Seeber S et al. Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic cell transplantation. Intern J Clin Pharmacol Ther 2004; 42: 654-655.
6. Werner S, Mendoza A, Hilger RA, Erlacher M, Reichardt W, Lissat A et al. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer Chemother Pharmacol 2008; 62: 19-31.
7. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogenic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233-241.
8. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209-4216.
9. Markiewicz M, Wojciechowska M, Wylezoł, Woźniczka K, Giebel S, Wojnar J et al. Unrelated bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria - successful treatment despite multiple transplant related risk factors for hemolysis including major Kidd group incompatibility. Bone Marrow Transplant 2006; 37: 231-232.
10. Wachowiak J, Chybicka A, Kowalczyk J, Boruczkowski D, Górczyńska A, Wójcik B et al. Retrospective study on treosulfan-based preparative regimen for allogenic HSCT in children with hematological malignancies and high risk of conventional regimen related toxicity. Bone Marrow Transplant 2005; 35 (S2): 261.
11. Główka FK, Karaźniewicz-Łada M, Grund G, Wachowiak J. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. J Chromatogr B 2007; 850: 569-574.